Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study.
Martín-Richard M, Massutí B, Pineda E, Alonso V, Marmol M, Castellano D, Fonseca E, Galán A, Llanos M, Sala MA, Pericay C, Rivera F, Sastre J, Segura A, Quindós M, Maisonobe P; TTD (Tumores del Tracto Digestivo) Study Group. Martín-Richard M, et al. Among authors: maisonobe p. BMC Cancer. 2013 Sep 20;13:427. doi: 10.1186/1471-2407-13-427. BMC Cancer. 2013. PMID: 24053191 Free PMC article. Clinical Trial.
Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial.
Caron PJ, Bevan JS, Petersenn S, Flanagan D, Tabarin A, Prévost G, Maisonobe P, Clermont A; PRIMARYS Investigators. Caron PJ, et al. Among authors: maisonobe p. J Clin Endocrinol Metab. 2014 Apr;99(4):1282-90. doi: 10.1210/jc.2013-3318. Epub 2013 Jan 1. J Clin Endocrinol Metab. 2014. PMID: 24423301 Free PMC article. Clinical Trial.
Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study.
Neggers SJ, Pronin V, Balcere I, Lee MK, Rozhinskaya L, Bronstein MD, Gadelha MR, Maisonobe P, Sert C, van der Lely AJ; LEAD Study Group. Neggers SJ, et al. Among authors: maisonobe p. Eur J Endocrinol. 2015 Sep;173(3):313-23. doi: 10.1530/EJE-15-0215. Epub 2015 Jun 5. Eur J Endocrinol. 2015. PMID: 26047625 Free PMC article.
Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study.
Ruszniewski P, Valle JW, Lombard-Bohas C, Cuthbertson DJ, Perros P, Holubec L, Delle Fave G, Smith D, Niccoli P, Maisonobe P, Atlan P, Caplin ME; SYMNET study group. Ruszniewski P, et al. Among authors: maisonobe p. Dig Liver Dis. 2016 May;48(5):552-558. doi: 10.1016/j.dld.2015.12.013. Epub 2016 Jan 15. Dig Liver Dis. 2016. PMID: 26917486 Free article.
Lanreotide Autogel in the Treatment of Idiopathic Refractory Diarrhea: Results of an Exploratory, Controlled, Before and After, Open-label, Multicenter, Prospective Clinical Trial.
Bisschops R, De Ruyter V, Demolin G, Baert D, Moreels T, Pattyn P, Verhelst H, Lepoutre L, Arts J, Caenepeel P, Ooghe P, Codden T, Maisonobe P, Petrens E, Tack J. Bisschops R, et al. Among authors: maisonobe p. Clin Ther. 2016 Aug;38(8):1902-1911.e2. doi: 10.1016/j.clinthera.2016.06.012. Epub 2016 Aug 8. Clin Ther. 2016. PMID: 27423779 Clinical Trial.
Symptomatic treatment with lanreotide microparticles in inoperable bowel obstruction resulting from peritoneal carcinomatosis: a randomized, double-blind, placebo-controlled phase III study.
Mariani P, Blumberg J, Landau A, Lebrun-Jezekova D, Botton E, Beatrix O, Mayeur D, Herve R, Maisonobe P, Chauvenet L. Mariani P, et al. Among authors: maisonobe p. J Clin Oncol. 2012 Dec 10;30(35):4337-43. doi: 10.1200/JCO.2011.40.5712. Epub 2012 Oct 29. J Clin Oncol. 2012. PMID: 23109694 Clinical Trial.
Changes in Body Image in Patients with Prostate Cancer over 2 Years of Treatment with a Gonadotropin-Releasing Hormone Analogue (Triptorelin): Results from a Belgian Non-Interventional Study.
van den Driessche H, Mattelaer P, van Oyen P, Marchand W, Bar-Moshé O, Merckx L, Billiet I, Cabri P, Maisonobe P, De Ruyter V, Braeckman J. van den Driessche H, et al. Among authors: maisonobe p. Drugs Real World Outcomes. 2016 May 13;3(2):183-190. doi: 10.1007/s40801-016-0074-5. eCollection 2016 Jun. Drugs Real World Outcomes. 2016. PMID: 27398297 Free PMC article.
73 results